GlassScriptPhysician profile
Cristi Aitelli
NPI 1578773511
$957.63
in general payments reported to CMS, 2019-2025
23 companies · $188 in 2025
The $188 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2021: $58.02 · 2022: $177 · 2023: $149 · 2024: $178 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $514.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $164.50 | 2024-2025 | Rybrevant, Carvykti |
| Celgene Corporation | $125.30 | 2022-2024 | Reblozyl |
| Sirtex Medical INC | $111.88 | 2019 | |
| Novartis Pharmaceuticals Corporation | $78.31 | 2019-2022 | |
| Incyte Corporation | $49.55 | 2023-2025 | Monjuvi, Jakafi |
| Astrazeneca Pharmaceuticals LP | $48.51 | 2019-2025 | |
| Tempus Ai, INC | $39.15 | 2024 | |
| Genzyme Corporation | $34.32 | 2019-2024 | |
| Abbvie INC. | $31.54 | 2023 | Venclexta |
| Lilly USA, LLC | $29.92 | 2019-2024 | Jaypirca |
| Array Biopharma INC | $27.32 | 2024 | Xalkori, Lorbrena, Braftovi |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $23.08 | 2022 | |
| Karyopharm Therapeutics INC. | $22.64 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $22.52 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $20.72 | 2023 | Monoferric |
| Eisai INC. | $20.53 | 2023 | |
| Janssen Scientific Affairs, LLC | $15.91 | 2019 | |
| Pfizer INC. | $15.03 | 2023 | |
| Mylan Institutional INC. | $14.50 | 2023 | Fulphila, Ogivri |
| Seagen INC. | $13.29 | 2022 | |
| Puma Biotechnology, INC. | $13.26 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cristi Aitelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.